Helus Pharma's HLP003 meets primary endpoint in Phase 3 depression trial
HELP•Helus Pharma said HLP003 met the primary and key secondary endpoints in its Phase 3 APPROACH trial as an adjunctive treatment for major depressive disorder. Symptoms improved versus placebo from Day 2 through Week 12, and response and remission rates also improved significantly.
1. Trial results
Helus Pharma announced positive topline results from its Phase 3 APPROACH trial of HLP003 as an adjunctive treatment for major depressive disorder. HLP003 met the primary and key secondary endpoints, reducing depressive symptoms versus placebo from Day 2 through Week 12; response and remission rates also improved significantly.
2. Safety findings
Treatment was generally well tolerated. Three treatment-related serious adverse events were reported, and no new safety signals emerged.




